A detailed history of Klcm Advisors, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Klcm Advisors, Inc. holds 10,720 shares of ABBV stock, worth $1.85 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
10,720
Previous 22,614 52.6%
Holding current value
$1.85 Million
Previous $3.88 Million 45.44%
% of portfolio
0.26%
Previous 0.49%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$163.84 - $199.33 $1.95 Million - $2.37 Million
-11,894 Reduced 52.6%
10,720 $2.12 Million
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $290,231 - $338,925
-1,875 Reduced 7.66%
22,614 $3.88 Million
Q1 2024

May 16, 2024

SELL
$159.82 - $182.1 $82,786 - $94,327
-518 Reduced 2.07%
24,489 $4.46 Million
Q4 2023

Jan 30, 2024

SELL
$137.6 - $154.97 $34,124 - $38,432
-248 Reduced 0.98%
25,007 $3.88 Million
Q3 2023

Nov 07, 2023

BUY
$133.59 - $154.65 $164,850 - $190,838
1,234 Added 5.14%
25,255 $3.76 Million
Q2 2023

Aug 08, 2023

BUY
$132.51 - $164.9 $1.77 Million - $2.21 Million
13,384 Added 125.82%
24,021 $3.24 Million
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $64,206 - $73,943
444 Added 4.36%
10,637 $1.7 Million
Q4 2022

Feb 10, 2023

SELL
$138.31 - $165.87 $9,543 - $11,445
-69 Reduced 0.67%
10,193 $1.65 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $148,973 - $170,862
1,110 Added 12.13%
10,262 $1.38 Million
Q2 2022

Aug 04, 2022

BUY
$137.62 - $174.96 $249,505 - $317,202
1,813 Added 24.7%
9,152 $1.4 Million
Q4 2021

Jan 31, 2022

SELL
$107.43 - $135.93 $109,578 - $138,648
-1,020 Reduced 12.2%
7,339 $994,000
Q3 2021

Nov 16, 2021

SELL
$106.4 - $120.78 $40,325 - $45,775
-379 Reduced 4.34%
8,359 $902,000
Q2 2021

Aug 03, 2021

SELL
$105.21 - $117.21 $100,685 - $112,169
-957 Reduced 9.87%
8,738 $984,000
Q1 2021

Apr 21, 2021

BUY
$102.3 - $112.62 $20,460 - $22,524
200 Added 2.11%
9,695 $1.05 Million
Q4 2020

Jan 26, 2021

SELL
$80.49 - $108.67 $2,414 - $3,260
-30 Reduced 0.31%
9,495 $1.02 Million
Q3 2020

Nov 03, 2020

BUY
$85.91 - $100.83 $3,006 - $3,529
35 Added 0.37%
9,525 $834,000
Q1 2020

May 13, 2020

BUY
$64.5 - $97.79 $2,257 - $3,422
35 Added 0.37%
9,490 $723,000
Q4 2019

Feb 04, 2020

SELL
$72.13 - $90.25 $61,310 - $76,712
-850 Reduced 8.25%
9,455 $837,000
Q3 2019

Nov 12, 2019

BUY
$62.98 - $75.72 $15,745 - $18,930
250 Added 2.49%
10,305 $780,000
Q2 2019

Aug 15, 2019

BUY
$65.7 - $83.98 $2,956 - $3,779
45 Added 0.45%
10,055 $731,000
Q1 2019

May 14, 2019

BUY
$77.14 - $90.79 $78,374 - $92,242
1,016 Added 11.3%
10,010 $807,000
Q4 2018

Feb 14, 2019

SELL
$77.85 - $96.01 $35,032 - $43,204
-450 Reduced 4.76%
8,994 $829,000
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $266 - $296
-3 Reduced 0.03%
9,444 $893,000
Q2 2018

Aug 09, 2018

BUY
$89.78 - $106.23 $69,848 - $82,646
778 Added 8.97%
9,447 $875,000
Q1 2018

May 10, 2018

SELL
$92.01 - $123.21 $237,477 - $318,005
-2,581 Reduced 22.94%
8,669 $821,000
Q4 2017

Feb 15, 2018

SELL
$89.56 - $98.21 $134,340 - $147,315
-1,500 Reduced 11.76%
11,250 $1.09 Million
Q3 2017

Nov 14, 2017

SELL
$69.85 - $89.22 $55,879 - $71,376
-800 Reduced 5.9%
12,750 $1.13 Million
Q2 2017

Aug 15, 2017

BUY
N/A
13,550
13,550 $983,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $306B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Klcm Advisors, Inc. Portfolio

Follow Klcm Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Klcm Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Klcm Advisors, Inc. with notifications on news.